{"id":54,"date":"2019-04-02T16:32:27","date_gmt":"2019-04-02T16:32:27","guid":{"rendered":"http:\/\/f0c1857d78.nxcli.net\/tumor\/?page_id=54"},"modified":"2019-04-08T20:34:53","modified_gmt":"2019-04-08T20:34:53","slug":"the-alliance-for-clinical-trials-in-neuro-oncology","status":"publish","type":"page","link":"https:\/\/newsletters.aans.org\/tumor\/tumor-section-spring-2019\/the-alliance-for-clinical-trials-in-neuro-oncology\/","title":{"rendered":"The Alliance for Clinical Trials in Neuro-Oncology"},"content":{"rendered":"<h4>About the Alliance for Clinical Trials in Oncology<\/h4>\n<p><em>The AANS\/CNS Tumor Section has implemented a collaboration with the Alliance for Clinical Trials in Oncology to facilitate cooperative efforts between neurosurgeons, neuro-oncologists and radiation oncologists at the national level to more efficiently support neuro-oncology clinical trials. Each issue of the Tumor Section Newsletter will highlight a clinical trial that is being sponsored by the Alliance or presented at one of the semi-annual meetings and may be of interest to neurosurgeons. Additional information regarding the Alliance is available <a href=\"https:\/\/allianceforclinicaltrialsinoncology.org\/main\/\">on the website<\/a>. <\/em><\/p>\n<p>Clinical trials highlighted in prior newsletters included:<\/p>\n<ul>\n<li data-gc-list-depth=\"1\" data-gc-list-style=\"bullet\">Phase I\/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Na\u00efve Patients With Recurrent Glioblastoma Multiforme\n<ul>\n<li data-gc-list-depth=\"2\" data-gc-list-style=\"bullet\">PI: Evanthia Galanis, MD, Mayo Clinic<\/li>\n<\/ul>\n<\/li>\n<li data-gc-list-depth=\"1\" data-gc-list-style=\"bullet\">A phase II\/III randomized trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma with MGMT promotor hypermethylation\n<ul>\n<li data-gc-list-depth=\"2\" data-gc-list-style=\"bullet\">PI: Jann Sarkaria, MD, Mayo Clinic<\/li>\n<\/ul>\n<\/li>\n<li data-gc-list-depth=\"1\" data-gc-list-style=\"bullet\">Phase II trial of SMO\/AKT\/NF2 inhibitors in progressive meningiomas with SMO\/AKT\/NF2 mutations\n<ul>\n<li data-gc-list-depth=\"2\" data-gc-list-style=\"bullet\">PI: Priscilla Brastianos, MD, Massachusetts General Hospital<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>The clinical trial highlighted in this report is \u201cStereotactic Radiosurgery compared with whole brain radiotherapy (WBRT) for 5-15 brain metastases.\u201d The role of Stereotactic Radiosurgery (SRS) in treating less than five metastases is clearer, and clinical studies have demonstrated superior results to WBRT in terms of neurocognitive side effects. The use of SRS in treating a larger number of brain metastases is more controversial. Neurosurgeons who routinely see patients with brain metastases will be interested in this trial, as it influences treatment paradigms offered to patients.<\/p>\n<p>This phase 3 clinical trial will enroll patients with 5-15 non-hematopoietic brain metastases. All brain metastases will be less than 2.5 cm in maximal diameter. Patients will be randomized to:<\/p>\n<ul>\n<li data-gc-list-depth=\"1\" data-gc-list-style=\"bullet\">Arm A: WBRT (30Gy in 10 fractions) + memantine<\/li>\n<li data-gc-list-depth=\"1\" data-gc-list-style=\"bullet\">Arm B: SRS (18-20 Gy hypofractionated or 22Gy single fraction)<\/li>\n<\/ul>\n<p>Primary outcome measures:<\/p>\n<ul>\n<li data-gc-list-depth=\"1\" data-gc-list-style=\"bullet\">Compare overall survival between the two treatment arms<\/li>\n<li data-gc-list-depth=\"1\" data-gc-list-style=\"bullet\">Compare neurocognitive PFS between the two treatment arms<\/li>\n<\/ul>\n<p>Secondary objectives:<\/p>\n<ul>\n<li data-gc-list-depth=\"1\" data-gc-list-style=\"bullet\">Time to CNS progression<\/li>\n<li data-gc-list-depth=\"1\" data-gc-list-style=\"bullet\">Differences in CNS failure patterns<\/li>\n<li data-gc-list-depth=\"1\" data-gc-list-style=\"bullet\">Number of salvage procedures following SRS compared to WBRT<\/li>\n<\/ul>\n<p>The estimated enrollment is 206 patients. The PI is Michael Chan, MD, FAANS, at Wake Forest. Further information regarding this clinical trial is on the Alliance website at allianceforclinicaltrialsinoncology.org or at clinicaltrials.gov. A list of ongoing trials sponsored by the Alliance can be accessed via the Alliance website as well.<\/p>\n<p>The spring Alliance for Clinical Trials in Oncology meeting is Saturday, May 11, 2019 in Chicago.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>About the Alliance for Clinical Trials in Oncology The AANS\/CNS Tumor Section has implemented a collaboration with the Alliance for Clinical Trials in Oncology to facilitate cooperative efforts between neurosurgeons, neuro-oncologists and radiation oncologists at the national level to more efficiently support neuro-oncology clinical trials. Each issue of the Tumor Section Newsletter will highlight a [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":34,"menu_order":12,"comment_status":"closed","ping_status":"closed","template":"NewsletterTOC.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-54","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The Alliance for Clinical Trials in Neuro-Oncology - Tumor News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/newsletters.aans.org\/tumor\/tumor-section-spring-2019\/the-alliance-for-clinical-trials-in-neuro-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Alliance for Clinical Trials in Neuro-Oncology - Tumor News\" \/>\n<meta property=\"og:description\" content=\"About the Alliance for Clinical Trials in Oncology The AANS\/CNS Tumor Section has implemented a collaboration with the Alliance for Clinical Trials in Oncology to facilitate cooperative efforts between neurosurgeons, neuro-oncologists and radiation oncologists at the national level to more efficiently support neuro-oncology clinical trials. Each issue of the Tumor Section Newsletter will highlight a [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/newsletters.aans.org\/tumor\/tumor-section-spring-2019\/the-alliance-for-clinical-trials-in-neuro-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Tumor News\" \/>\n<meta property=\"article:modified_time\" content=\"2019-04-08T20:34:53+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/tumor-section-spring-2019\\\/the-alliance-for-clinical-trials-in-neuro-oncology\\\/\",\"url\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/tumor-section-spring-2019\\\/the-alliance-for-clinical-trials-in-neuro-oncology\\\/\",\"name\":\"The Alliance for Clinical Trials in Neuro-Oncology - Tumor News\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#website\"},\"datePublished\":\"2019-04-02T16:32:27+00:00\",\"dateModified\":\"2019-04-08T20:34:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/tumor-section-spring-2019\\\/the-alliance-for-clinical-trials-in-neuro-oncology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/tumor-section-spring-2019\\\/the-alliance-for-clinical-trials-in-neuro-oncology\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/tumor-section-spring-2019\\\/the-alliance-for-clinical-trials-in-neuro-oncology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tumor Section Spring 2019\",\"item\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/tumor-section-spring-2019\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"The Alliance for Clinical Trials in Neuro-Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#website\",\"url\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/\",\"name\":\"Tumor News\",\"description\":\"Just another AANS Newsletter Sites site\",\"publisher\":{\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#organization\",\"name\":\"Tumor News\",\"url\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/newsletters.aans.org\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2024\\\/11\\\/JST.2024.logo_.png\",\"contentUrl\":\"https:\\\/\\\/newsletters.aans.org\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2024\\\/11\\\/JST.2024.logo_.png\",\"width\":2336,\"height\":2294,\"caption\":\"Tumor News\"},\"image\":{\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Alliance for Clinical Trials in Neuro-Oncology - Tumor News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/newsletters.aans.org\/tumor\/tumor-section-spring-2019\/the-alliance-for-clinical-trials-in-neuro-oncology\/","og_locale":"en_US","og_type":"article","og_title":"The Alliance for Clinical Trials in Neuro-Oncology - Tumor News","og_description":"About the Alliance for Clinical Trials in Oncology The AANS\/CNS Tumor Section has implemented a collaboration with the Alliance for Clinical Trials in Oncology to facilitate cooperative efforts between neurosurgeons, neuro-oncologists and radiation oncologists at the national level to more efficiently support neuro-oncology clinical trials. Each issue of the Tumor Section Newsletter will highlight a [&hellip;]","og_url":"https:\/\/newsletters.aans.org\/tumor\/tumor-section-spring-2019\/the-alliance-for-clinical-trials-in-neuro-oncology\/","og_site_name":"Tumor News","article_modified_time":"2019-04-08T20:34:53+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/newsletters.aans.org\/tumor\/tumor-section-spring-2019\/the-alliance-for-clinical-trials-in-neuro-oncology\/","url":"https:\/\/newsletters.aans.org\/tumor\/tumor-section-spring-2019\/the-alliance-for-clinical-trials-in-neuro-oncology\/","name":"The Alliance for Clinical Trials in Neuro-Oncology - Tumor News","isPartOf":{"@id":"https:\/\/newsletters.aans.org\/tumor\/#website"},"datePublished":"2019-04-02T16:32:27+00:00","dateModified":"2019-04-08T20:34:53+00:00","breadcrumb":{"@id":"https:\/\/newsletters.aans.org\/tumor\/tumor-section-spring-2019\/the-alliance-for-clinical-trials-in-neuro-oncology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/newsletters.aans.org\/tumor\/tumor-section-spring-2019\/the-alliance-for-clinical-trials-in-neuro-oncology\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/newsletters.aans.org\/tumor\/tumor-section-spring-2019\/the-alliance-for-clinical-trials-in-neuro-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/newsletters.aans.org\/tumor\/"},{"@type":"ListItem","position":2,"name":"Tumor Section Spring 2019","item":"https:\/\/newsletters.aans.org\/tumor\/tumor-section-spring-2019\/"},{"@type":"ListItem","position":3,"name":"The Alliance for Clinical Trials in Neuro-Oncology"}]},{"@type":"WebSite","@id":"https:\/\/newsletters.aans.org\/tumor\/#website","url":"https:\/\/newsletters.aans.org\/tumor\/","name":"Tumor News","description":"Just another AANS Newsletter Sites site","publisher":{"@id":"https:\/\/newsletters.aans.org\/tumor\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/newsletters.aans.org\/tumor\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/newsletters.aans.org\/tumor\/#organization","name":"Tumor News","url":"https:\/\/newsletters.aans.org\/tumor\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/newsletters.aans.org\/tumor\/#\/schema\/logo\/image\/","url":"https:\/\/newsletters.aans.org\/wp-content\/uploads\/sites\/5\/2024\/11\/JST.2024.logo_.png","contentUrl":"https:\/\/newsletters.aans.org\/wp-content\/uploads\/sites\/5\/2024\/11\/JST.2024.logo_.png","width":2336,"height":2294,"caption":"Tumor News"},"image":{"@id":"https:\/\/newsletters.aans.org\/tumor\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/pages\/54","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/comments?post=54"}],"version-history":[{"count":4,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/pages\/54\/revisions"}],"predecessor-version":[{"id":181,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/pages\/54\/revisions\/181"}],"up":[{"embeddable":true,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/pages\/34"}],"wp:attachment":[{"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/media?parent=54"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}